FDA Approves Hibsago: First Antisense Drug for Hepatitis B
FDA approves Hibsago (bepirovirsen) with antivirals for chronic hepatitis B; 19% kept viral control off treatment in trials, with a boxed warning.
FDA approves Hibsago (bepirovirsen) with antivirals for chronic hepatitis B; 19% kept viral control off treatment in trials, with a boxed warning.